Show simple item record Hamadeh, Lina Enshaei, Amir Schwab, Claire Alonso, Cristina N Attarbaschi, Andishe Barbany, Gisela den Boer, Monique L Boer, Judith M Braun, Marcin Dalla Pozza, Luciano Elitzur, Sarah Emerenciano, Mariana Fechina, Larisa Felice, Maria Sara Fronkova, Eva Haltrich, Irén Heyman, Mats M Horibe, Keizo Imamura, Toshihiko Jeison, Marta Kovács, Gábor Kuiper, Roland P Mlynarski, Wojciech Nebral, Karin Ivanov Öfverholm, Ingegerd Pastorczak, Agata Pieters, Rob Piko, Henriett Pombo-de-Oliveira, Maria S Rubio, Patricia Strehl, Sabine Stary, Jan Sutton, Rosemary Trka, Jan Tsaur, Grigory Venn, Nicola Vora, Ajay Yano, Mio Harrison, Christine J Moorman, Anthony V 2020-09-10T06:36:57Z 2020-09-10T06:36:57Z 2019
dc.identifier.citation journalVolume=3;journalIssueNumber=2;journalTitle=BLOOD ADVANCES;pagerange=148-157;journalAbbreviatedTitle=BLOOD ADVANCES;
dc.identifier.uri doi:10.1182/bloodadvances.2018025718
dc.description.abstract Genetic abnormalities provide vital diagnostic and prognostic information in pediatric acute lymphoblastic leukemia (ALL) and are increasingly used to assign patients to risk groups. We recently proposed a novel classifier based on the copy-number alteration (CNA) profile of the 8 most commonly deleted genes in B-cell precursor ALL. This classifier defined 3 CNA subgroups in consecutive UK trials and was able to discriminate patients with intermediate-risk cytogenetics. In this study, we sought to validate the United Kingdom ALL (UKALL)-CNA classifier and reevaluate the interaction with cytogenetic risk groups using individual patient data from 3239 cases collected from 12 groups within the International BFM Study Group. The classifier was validated and defined 3 risk groups with distinct event-free survival (EFS) rates: good (88%), intermediate (76%), and poor (68%) (P < .001). There was no evidence of heterogeneity, even within trials that used minimal residual disease to guide therapy. By integrating CNA and cytogenetic data, we replicated our original key observation that patients with intermediate-risk cytogenetics can be stratified into 2 prognostic subgroups. Group A had an EFS rate of 86% (similar to patients with good-risk cytogenetics), while group B patients had a significantly inferior rate (73%, P < .001). Finally, we revised the overall genetic classification by defining 4 risk groups with distinct EFS rates: very good (91%), good (81%), intermediate (73%), and poor (54%), P < .001. In conclusion, the UKALL-CNA classifier is a robust prognostic tool that can be deployed in different trial settings and used to refine established cytogenetic risk groups.
dc.format.extent 148-157
dc.relation.ispartof urn:issn:2473-9529
dc.title Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL
dc.type Journal Article 2019-08-16T06:25:19Z
dc.language.rfc3066 en
dc.rights.holder NULL
dc.identifier.mtmt 30420807
dc.identifier.wos 000458435200009
dc.identifier.pubmed 30651283
dc.contributor.department SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.institution Semmelweis Egyetem

Files in this item

This file is available only from Semmelweis network


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account